Total Payments
$19,789
2024 Payments
$2,509
Companies
63
Transactions
1,051
Medicare Patients
3,658
Medicare Billing
$422,769
Payment Breakdown by Category
Food & Beverage$19,677 (99.4%)
Education$111.76 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $19,677 | 1,047 | 99.4% |
| Education | $111.76 | 4 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $1,462 | 44 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $1,389 | 69 | $0 (2024) |
| Biogen, Inc. | $1,347 | 79 | $0 (2024) |
| UCB, Inc. | $1,099 | 53 | $0 (2024) |
| GENZYME CORPORATION | $1,023 | 39 | $0 (2023) |
| Neurocrine Biosciences, Inc. | $958.79 | 44 | $0 (2024) |
| Avanir Pharmaceuticals, Inc. | $891.76 | 86 | $0 (2022) |
| ACADIA Pharmaceuticals Inc | $771.21 | 50 | $0 (2024) |
| ABBVIE INC. | $745.53 | 55 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $670.48 | 31 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,509 | 122 | ABBVIE INC. ($245.37) |
| 2023 | $2,378 | 124 | Otsuka America Pharmaceutical, Inc. ($237.10) |
| 2022 | $2,241 | 116 | Biohaven Pharmaceutical Holding Company Ltd. ($241.15) |
| 2021 | $2,681 | 138 | AstraZeneca Pharmaceuticals LP ($271.60) |
| 2020 | $2,064 | 102 | Amgen Inc. ($330.40) |
| 2019 | $3,040 | 163 | Amgen Inc. ($458.19) |
| 2018 | $2,447 | 140 | Amgen Inc. ($481.49) |
| 2017 | $2,427 | 146 | GENZYME CORPORATION ($418.13) |
All Payment Transactions
1,051 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Lilly USA, LLC | AMYVID (Drug), KISUNLA | Food and Beverage | In-kind items and services | $23.61 | General |
| Category: Neuroscience | ||||||
| 12/16/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $34.91 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $10.96 | General |
| Category: Neuropsychiatry | ||||||
| 12/09/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: PAIN | ||||||
| 12/06/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: EPILEPSY | ||||||
| 12/03/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $21.32 | General |
| Category: NEUROLOGY | ||||||
| 11/22/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $24.23 | General |
| Category: Neuropsychiatry | ||||||
| 11/21/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $27.06 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/20/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $28.55 | General |
| 11/18/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $33.67 | General |
| Category: Neurology | ||||||
| 11/15/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: Central Nervous System | ||||||
| 11/12/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $22.20 | General |
| 11/11/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $21.35 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/05/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $22.52 | General |
| Category: Neurology | ||||||
| 11/02/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2024 | Biogen, Inc. | SKYCLARYS (Drug) | Food and Beverage | In-kind items and services | $19.14 | General |
| Category: Neurology | ||||||
| 10/25/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $24.03 | General |
| Category: Neurology | ||||||
| 10/21/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $22.12 | General |
| Category: NEUROSCIENCE | ||||||
| 10/15/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: Neurology | ||||||
| 10/14/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $26.35 | General |
| Category: Neurology | ||||||
| 10/11/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $25.79 | General |
| Category: Central Nervous System | ||||||
| 10/08/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: Neuropsychiatry | ||||||
| 10/07/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $19.00 | General |
| Category: NEUROLOGY | ||||||
| 10/04/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: PAIN | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 701 | 1,116 | $219,816 | $92,435 |
| 2022 | 13 | 934 | 1,525 | $277,706 | $115,943 |
| 2021 | 13 | 945 | 1,342 | $245,329 | $104,873 |
| 2020 | 16 | 1,078 | 1,472 | $270,101 | $109,518 |
Total Patients
3,658
Total Services
5,455
Medicare Billing
$422,769
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 177 | 401 | $60,150 | $23,896 | 39.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 143 | 149 | $48,425 | $19,338 | 39.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 105 | 180 | $29,160 | $15,373 | 52.7% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 54 | 107 | $20,460 | $7,748 | 37.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 27 | 81 | $14,046 | $7,209 | 51.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 33 | 34 | $17,000 | $5,477 | 32.2% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 33 | 33 | $11,039 | $4,161 | 37.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 34 | 34 | $8,432 | $4,071 | 48.3% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2023 | 54 | 56 | $5,600 | $2,359 | 42.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 12 | 12 | $2,604 | $1,612 | 61.9% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 29 | 29 | $2,900 | $1,192 | 41.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 203 | 212 | $68,900 | $31,316 | 45.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 203 | 475 | $71,250 | $25,324 | 35.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 151 | 244 | $40,308 | $20,249 | 50.2% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 57 | 116 | $20,760 | $8,394 | 40.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 56 | 56 | $13,996 | $6,312 | 45.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 78 | $13,650 | $5,938 | 43.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 37 | 108 | $8,029 | $3,102 | 38.6% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2022 | 22 | 22 | $8,603 | $2,731 | 31.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 18 | 18 | $9,000 | $2,642 | 29.4% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2022 | 23 | 23 | $5,935 | $2,313 | 39.0% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2022 | 32 | 58 | $4,350 | $2,018 | 46.4% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2022 | 45 | 47 | $4,700 | $1,950 | 41.5% |
| 95910 | Nerve conduction, 7-8 studies | Facility | 2022 | 19 | 19 | $3,325 | $1,544 | 46.4% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2022 | 35 | 35 | $3,500 | $1,499 | 42.8% |
About Dr. Cornelius Mance, MD
Dr. Cornelius Mance, MD is a Neurology healthcare provider based in Hixson, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1861586331.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cornelius Mance, MD has received a total of $19,789 in payments from pharmaceutical and medical device companies, with $2,509 received in 2024. These payments were reported across 1,051 transactions from 63 companies. The most common payment nature is "Food and Beverage" ($19,677).
As a Medicare-enrolled provider, Mance has provided services to 3,658 Medicare beneficiaries, totaling 5,455 services with total Medicare billing of $422,769. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Hixson, TN
- Active Since 10/02/2006
- Last Updated 09/02/2020
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1861586331
Products in Payments
- Aimovig (Biological) $1,263
- NUEDEXTA (Drug) $827.92
- INGREZZA (Drug) $788.48
- NUPLAZID (Drug) $771.21
- Briviact (Drug) $746.55
- AUBAGIO (Drug) $709.06
- NURTEC ODT (Drug) $686.91
- ZEPOSIA (Drug) $675.75
- TYSABRI (Biological) $644.64
- Fycompa (Drug) $504.77
- UBRELVY (Drug) $449.13
- VALTOCO (Drug) $445.92
- AJOVY (Drug) $439.58
- OXTELLAR XR (Drug) $423.86
- APTIOM (Drug) $417.24
- EMGALITY (Drug) $394.67
- QULIPTA (Drug) $370.18
- VYEPTI (Biological) $368.99
- TECFIDERA (Drug) $346.69
- AUSTEDO (Drug) $330.74
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.